Role of the Ambulatory Assessed Apnea-Hypopnea Index for Predicting Recurring Atrial Fibrillation After Ablation Therapy

Author(s):  
Teresa Trenkwalder ◽  
Christian Grebmer ◽  
Madeleine Tydecks ◽  
Patrick Blažek ◽  
Marc Kottmaier ◽  
...  
Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Masao Sakabe ◽  
Kristina Lemola ◽  
Katsuyoshi Chiba ◽  
Grigorios Katsouras ◽  
Akiko Shiroshita-Takeshita ◽  
...  

Background : Pulmonary vein (PV) activity is crucial in some forms of clinical atrial fibrillation (AF), particularly paroxysmal lone AF. The precise importance of PVs in AF associated with structural heart disease is less clear. Some evidence suggests that PVs may be important for AF in experimentally-remodeled atrial substrates, e.g. atrial-tachycardia remodeling (ATR) and congestive heart failure (CHF)-induced structural remodeling, but contradictory findings also exist. This study assessed the role of PVs in canine remodeling-associated AF by evaluating the changes induced by PV-LA disconnection via encircling epicardial ablation. Methods: AF was induced before and after complete isolation of all PVs in dogs with: ATR induced by atrial tachypacing (400 bpm x 1 wk; with AV block and 80 bpm ventricular pacing to control ventricular rate, n=5); and CHF induced by ventricular tachypacing (VTP, 240 bpm x 2 wks, n=7). Electrophysiological measurements and AF mapping with 240 unipolar atrial electro-grams in both atria and all PVs were also obtained before and after PV isolation. Results ATR reduced atrial ERPs and ERP rate adaptation. The shortest AF cycle length (AFCL) in each ATR dog was recorded from PVs (mean 84±3 ms), but the mean AFCL in each of the PVs (range 97–103 ms) was not different from the mean AFCL at LA sites (98 –103 ms). PV ablation did not affect AF duration in ATR dogs (mean 284±265 pre- vs. 304±225 s post-ablation, P=NS), nor did it significantly alter RA or LA AFCL. In CHF dogs, ERPs and ERP rate adaptation were preserved. The shortest AFCL was recorded in PVs in 2 dogs (108,112 ms) and in the left side of Bachmann’s bundle in 3 (97–117 ms). PV ablation failed to alter AF duration in CHF dogs (mean 778±203 pre- vs. 644±206 s post-ablation), and increased AFCL in RA and LA slightly (10 –15%) but not significantly. Conclusions : Uncoupling of the PVs from the LA fails to significantly affect the AF substrate in 2 clinically-relevant animal paradigms of AF-promoting atrial remodeling. These findings suggest that in the presence of a favorable atrial substrate for AF the PVs are not needed for AF maintenance, and are consistent with clinical observations that complete PV isolation may not be essential for effective ablation therapy of all groups of AF patients.


2020 ◽  
Vol 04 (03) ◽  
pp. 291-302
Author(s):  
Mariam F. Eskander ◽  
Christopher T. Aquina ◽  
Aslam Ejaz ◽  
Timothy M. Pawlik

AbstractAdvances in the field of surgical oncology have turned metastatic colorectal cancer of the liver from a lethal disease to a chronic disease and have ushered in a new era of multimodal therapy for this challenging illness. A better understanding of tumor behavior and more effective systemic therapy have led to the increased use of neoadjuvant therapy. Surgical resection remains the gold standard for treatment but without the size, distribution, and margin restrictions of the past. Lesions are considered resectable if they can safely be removed with tumor-free margins and a sufficient liver remnant. Minimally invasive liver resections are a safe alternative to open surgery and may offer some advantages. Techniques such as portal vein embolization, association of liver partition with portal vein ligation for staged hepatectomy, and radioembolization can be used to grow the liver remnant and allow for resection. If resection is not possible, nonresectional ablation therapy, including radiofrequency and microwave ablation, can be performed alone or in conjunction with resection. This article presents the most up-to-date literature on resection and ablation, with a discussion of current controversies and future directions.


2004 ◽  
Vol 52 (S 1) ◽  
Author(s):  
S Dhein ◽  
A Boldt ◽  
J Garbade ◽  
L Polontchouk ◽  
U Wetzel ◽  
...  

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 2406-PUB
Author(s):  
KONSTANTINA KANELLOPOULOU ◽  
IOANNIS L. MATSOUKIS ◽  
ASIMINA GANOTOPOULOU ◽  
THEODORA ATHANASOPOULOU ◽  
CHRYSOULA TRIANTAFILLOPOULOU ◽  
...  

2019 ◽  
Vol 26 (5) ◽  
pp. 837-854 ◽  
Author(s):  
Effimia Zacharia ◽  
Nikolaos Papageorgiou ◽  
Adam Ioannou ◽  
Gerasimos Siasos ◽  
Spyridon Papaioannou ◽  
...  

During the last few years, a significant number of studies have attempted to clarify the underlying mechanisms that lead to the presentation of atrial fibrillation (AF). Inflammation is a key component of the pathophysiological processes that lead to the development of AF; the amplification of inflammatory pathways triggers AF, and, in tandem, AF increases the inflammatory state. Indeed, the plasma levels of several inflammatory biomarkers are elevated in patients with AF. In addition, the levels of specific inflammatory biomarkers may provide information regarding to the AF duration. Several small studies have assessed the role of anti-inflammatory treatment in atrial fibrillation but the results have been contradictory. Large-scale studies are needed to evaluate the role of inflammation in AF and whether anti-inflammatory medications should be routinely administered to patients with AF.


Sign in / Sign up

Export Citation Format

Share Document